GenomOncology
PrivateLast Round
Debt
Feb 12, 2021
Total Funding Raised
$4.13M
Company Overview
GenomOncology operates in Healthcare & Life Sciences and is based in Cleveland, Ohio. Its latest recorded funding round was a Debt round in February 2021.
GenomOncology is a healthtech company that provides a software platform to transform complex clinical and molecular genomic data into actionable intelligence for personalized patient care.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Healthcare Analytics, Data Integration, Clinical Trials
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GenomOncology Comparables
Compare GenomOncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genomate Health | 82% | |
| CureMatch | 81% | |
| VieCure | 81% |
For institutional investors. Book with your work email.
GenomOncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Feb 12, 2021 | ||||
| Debt | Apr 27, 2020 | ||||
| Convertible Debt | Nov 22, 2019 | ||||
| Series A | Sep 7, 2016 | ||||
| Seed | Feb 4, 2014 | ||||
Seed | Jun 5, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GenomOncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KeyBank | Debt |
| JumpStart Ventures | Seed, Series A |
| Zapis Capital Group | Seed |
| TriStar Health Partners | Seed |
| North Coast Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 11, 2025
Partnered with the Glioblastoma Foundation to accelerate precision treatment.
- Feb 12, 2021
$637K debt round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 5, 2026
GenomOncology LLC introduces optional artificial intelligence (AI)-driven workflows in GO Pathology Workbench that use an AI-enhanced algorithm to classify prioritized variants and draft clinical interpretations for reviewer approval on Nov 5th '26.
- partners_withAug 20, 2026
GenomOncology LLC partners with Pillar Biosciences, Inc. in Feb '25 to pair clinical decision support software with targeted NGS panels for faster, more personalized cancer treatment guidance.
For institutional investors. Book with your work email.
GenomOncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GenomOncology's valuation, stock price, and market status.
Is GenomOncology a public or private company?
GenomOncology is a private company.
What is the current stock price of GenomOncology?
GenomOncology is a private company, so its shares have no public market price. Caplight tracks GenomOncology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GenomOncology worth (valuation)?
Valuation information for GenomOncology is not publicly available.
Can I buy GenomOncology stock?
GenomOncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GenomOncology's last funding round?
GenomOncology's most recent funding round was Debt on February 12, 2021.
Who are the main investors in GenomOncology?
Key investors in GenomOncology include Zapis Capital Group, TriStar Health Partners.
Will GenomOncology IPO soon?
No public IPO plans have been announced for GenomOncology.
How can I track GenomOncology secondary market activity?
Caplight tracks bids, offers, and trades in GenomOncology's shares on secondary markets.